Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1RN | P18510 | 8/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 8/20 | 0.57 |
| ▸ | NPY4R | P50391 | 7/20 | 0.57 |
| ▸ | NPY1R | P25929 | 5/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 6/20 | 0.54 |
| ▸ | NPY2R | P49146 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930564 | 1.00 | IL1RN (0.57) | IL1RNERAP2NPY4RNPY1RERAP1 | |
| SCHEMBL8202889 | 0.90 | IL1RN (0.55) | IL1RNERAP2NPY4RNPY1RERAP1 | |
| SCHEMBL8203303 | 0.85 | CAPN1 (0.62) | IL1RNERAP2NPY4RNPY1RERAP1 | |
| SCHEMBL8203393 | 0.81 | NPY4R (0.47) | IL1RNERAP2NPY4RNPY1RERAP1 | |
| SCHEMBL26817750 | 0.77 | TSHR (0.56) | IL1RNERAP2TSHRALDH1A1THRB | |
| SCHEMBL26817919 | 0.77 | TSHR (0.54) | IL1RNERAP2NPY4RNPY1RERAP1 | |
| SCHEMBL12907717 | 0.76 | FOLH1 (0.72) | FOLH1 | |
| SCHEMBL15223599 | 0.75 | ALDH1A1 (0.69) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL28069215 | 0.75 | ERAP2 (0.60) | IL1RNERAP2NPY4RNPY1RERAP1 | |
| SCHEMBL28069213 | 0.75 | ERAP2 (0.60) | IL1RNERAP2NPY4RNPY1RERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434762-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | UNIVERSITY OF CANTERBURY (NZ) | 2016-09-06 | — | — | US | disclosed |
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | LINCOLN UNIVERSITY (NZ) | 2014-07-10 | — | — | US | disclosed |
| US-8710178-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | LINCOLN UNIVERSITY (NZ) | 2014-04-29 | — | — | US | disclosed |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | UNIVERSITY OF CANTERBURY (NZ) | 2011-01-27 | — | — | US | disclosed |
| WO-2008048121-A2 | MACROCYCLIC CYSTEINE PROTEASE INHIBITORS AND COMPOSITIONS THEREOF | LINCOLN UNIVERSITY (NZ) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | IL1RN 1424/4885ERAP2 67/4885NPY4R 4752/4885 |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | IL1RN 1424/4885ERAP2 67/4885NPY4R 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.